LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 1954

Search options

  1. Article ; Online: Cancer Prescriptions and Impact on Climate Change: Real or Imagined?

    Kohli, Manish

    JCO oncology practice

    2023  Volume 19, Issue 9, Page(s) 697–699

    MeSH term(s) Humans ; Climate Change ; Neoplasms/complications ; Neoplasms/epidemiology
    Language English
    Publishing date 2023-08-21
    Publishing country United States
    Document type Editorial ; Comment
    ZDB-ID 3028198-2
    ISSN 2688-1535 ; 2688-1527
    ISSN (online) 2688-1535
    ISSN 2688-1527
    DOI 10.1200/OP.23.00424
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: National prevention and cancer screening programs in India

    Manish Kohli

    MAMC Journal of Medical Sciences, Vol 2, Iss 2, Pp 61-

    Why bother?

    2016  Volume 62

    Keywords Medicine ; R
    Language English
    Publishing date 2016-01-01T00:00:00Z
    Publisher Wolters Kluwer Medknow Publications
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  3. Article: Anti-Nuclear Antibody-Negative Lupus Nephritis or Post-Infectious Glomerulonephritis: Diagnostic Dilemma in a Young Male.

    Bharati, Joyita / Quaiser, Saif / Nada, Ritambhra / Ramachandran, Raja / Kohli, Harbir Singh / Rathi, Manish

    Indian journal of nephrology

    2020  Volume 31, Issue 4, Page(s) 394–397

    Abstract: Proliferative lupus nephritis (LN) is histologically characterized by endocapillary hypercellularity and large immune deposits on light microscopy. Immunofluorescence shows almost all immunoglobulins and complement staining. The presence of antinuclear ... ...

    Abstract Proliferative lupus nephritis (LN) is histologically characterized by endocapillary hypercellularity and large immune deposits on light microscopy. Immunofluorescence shows almost all immunoglobulins and complement staining. The presence of antinuclear antibodies (ANA) is important for diagnosing systemic lupus erythematosus (SLE). Absence of ANA rules out the possibility of SLE according to the 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for SLE. We report a young boy with fever, nephrotic-nephritic syndrome and pancytopenia consistent with hemophagocytic lymphohistiocytosis. Renal biopsy was consistent with LN; however, his initial ANA was negative. In view of pathological features of LN and persistent pancytopenia, high dose steroid therapy was started. Repeat ANA, done during the illness, turned positive. In this report, we describe the relevance of pathological patterns and the uncertainties of ANA positivity in making a diagnosis of SLE.
    Language English
    Publishing date 2020-11-11
    Publishing country India
    Document type Case Reports
    ZDB-ID 2134388-3
    ISSN 1998-3662 ; 0971-4065
    ISSN (online) 1998-3662
    ISSN 0971-4065
    DOI 10.4103/ijn.IJN_189_20
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Systematic Analysis of Tissue-Derived and Biofluid Extracellular Vesicle miRNAs Associated with Prostate Cancer.

    Larson, Jeevan / Ozen, Mehmet Ozgun / Kohli, Manish / Akin, Demir / Demirci, Utkan

    Advanced biology

    2023  Volume 7, Issue 7, Page(s) e2200327

    Abstract: Extracellular vesicles (EVs) are emerging as biomarker candidates for early detection of prostate cancer. Studies compare EV-microRNA (miRNA) expression in individuals with prostate cancer (PCa) with cancer-free samples for diagnostic purposes. The aim ... ...

    Abstract Extracellular vesicles (EVs) are emerging as biomarker candidates for early detection of prostate cancer. Studies compare EV-microRNA (miRNA) expression in individuals with prostate cancer (PCa) with cancer-free samples for diagnostic purposes. The aim of this study is to review miRNA signatures to investigate the overlap between miRNAs enriched in PCa tissue and miRNAs enriched in EVs isolated from subjects with PCa biofluids (i.e., urine, serum, and plasma). Signatures dysregulated in EVs from PCa biofluids and tissue are potentially associated with the primary tumor site and might be more indicative of PCa at an early stage. A systematic review of EV-derived miRNAs and a reanalysis of PCa tissue miRNA sequencing data for comparison is presented. Articles in the literature are screened for validated miRNA dysregulation in PCa and compared with TCGA primary PCa tumor data using DESeq2. This resulted in 190 dysregulated miRNAs being identified. Thirty-one eligible studies are identified, indicating 39 dysregulated EV-derived miRNAs. The top ten markers identified as significantly dysregulated in the PCa tissue dataset TCGA (e.g., miR-30b-3p, miR-210-3p, miR-126-3p, and miR-196a-5p) have a significant expression change in EVs with the same directionality in one or several statistically significant results. This analysis highlights several less frequently studied miRNAs in PCa literature.
    MeSH term(s) Male ; Humans ; MicroRNAs/genetics ; MicroRNAs/metabolism ; Prostatic Neoplasms/diagnosis ; Prostatic Neoplasms/genetics ; Prostatic Neoplasms/metabolism ; Extracellular Vesicles/genetics ; Extracellular Vesicles/metabolism ; Extracellular Vesicles/pathology
    Chemical Substances MicroRNAs
    Language English
    Publishing date 2023-06-09
    Publishing country Germany
    Document type Systematic Review ; Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, N.I.H., Extramural
    ISSN 2701-0198
    ISSN (online) 2701-0198
    DOI 10.1002/adbi.202200327
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Obinutuzumab in Refractory Phospholipase A2 receptor-Associated Membranous Nephropathy With Severe CKD.

    Naik, Sachin / Shukla, Shubham / Av, Niranjan / Kumar, Vinod / Sekar, Aravind / Nada, Ritambhra / Rathi, Manish / Kohli, Harbir Singh / Ramachandran, Raja

    Kidney international reports

    2023  Volume 8, Issue 4, Page(s) 942–943

    Language English
    Publishing date 2023-01-31
    Publishing country United States
    Document type Journal Article
    ISSN 2468-0249
    ISSN (online) 2468-0249
    DOI 10.1016/j.ekir.2023.01.035
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: Poor Outcome after Hospital Discharge in Patients with ESKD and COVID-19.

    Sethi, Jasmine / Kumar, Vivek / Yadav, Ashok K / Bharti, Joyita / Divyaveer, Smita S / Ramachandran, Raja / Rathi, Manish / Kohli, Harbir S

    Indian journal of nephrology

    2023  Volume 33, Issue 2, Page(s) 150–151

    Language English
    Publishing date 2023-02-20
    Publishing country India
    Document type Journal Article
    ZDB-ID 2134388-3
    ISSN 1998-3662 ; 0971-4065
    ISSN (online) 1998-3662
    ISSN 0971-4065
    DOI 10.4103/ijn.ijn_286_21
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article: Nematode Genome Announcement: A Draft Genome of Seed Gall Nematode,

    Singh, Ashish Kumar / Das, Antara / Joshi, Ila / Kumar, Manish / Kohli, Deshika / Pankaj / Gaikwad, Kishor / Jain, Pradeep Kumar / Sirohi, Anil

    Journal of nematology

    2023  Volume 55, Issue 1, Page(s) 20230031

    Abstract: ... Anguina ... ...

    Abstract Anguina tritici
    Language English
    Publishing date 2023-11-15
    Publishing country Poland
    Document type Journal Article
    ZDB-ID 410426-2
    ISSN 0022-300X
    ISSN 0022-300X
    DOI 10.2478/jofnem-2023-0031
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Current management of metastatic castration-sensitive prostate cancer.

    Kessel, Adam / Kohli, Manish / Swami, Umang

    Cancer treatment and research communications

    2021  Volume 28, Page(s) 100384

    Abstract: Prostate cancer affects one in nine men and once metastatic is incurable. The treatment for metastatic castration-sensitive prostate cancer (mCSPC) has evolved rapidly over the last decade with the addition of upfront intensification with novel hormonal ... ...

    Abstract Prostate cancer affects one in nine men and once metastatic is incurable. The treatment for metastatic castration-sensitive prostate cancer (mCSPC) has evolved rapidly over the last decade with the addition of upfront intensification with novel hormonal therapies (abiraterone, enzalutamide, apalutamide) or docetaxel in addition to androgen deprivation therapy. In this review, we discuss the phase III studies that lead to the approval of these upfront intensification therapies. We also review the recent approval of relugolix, the first oral, gonadotropin-releasing hormone antagonist for patients with advanced prostate cancer. A comparison of various agents is made and variables that can help in treatment selection are reviewed. We also summarize our current understanding of the role of germline and somatic alterations in the mCSPC setting. Finally, we review the ongoing clinical trials which can change the current treatment paradigm.
    MeSH term(s) Humans ; Male ; Prostatic Neoplasms, Castration-Resistant/drug therapy ; Prostatic Neoplasms, Castration-Resistant/pathology
    Language English
    Publishing date 2021-04-24
    Publishing country England
    Document type Journal Article ; Review
    ISSN 2468-2942
    ISSN (online) 2468-2942
    DOI 10.1016/j.ctarc.2021.100384
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Spectrum of Pneumonia in Renal Transplant Recipients: An Indian Experience.

    Govindan, Sukanya / Bagai, Sahil / Ramachandran, Raja / Kumar, Vivek / Rathi, Manish / Kohli, Harbir S / Sharma, Ashish / Gupta, Krishan Lal

    Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation

    2024  Volume 22, Issue Suppl 1, Page(s) 73–77

    Abstract: Objectives: Respiratory tract infections are life-threatening infections in solid-organ transplant recipients that pose risk to the graft and to the patient. This study was undertaken to examine the clinical and microbiological spectrum of pneumonia in ... ...

    Abstract Objectives: Respiratory tract infections are life-threatening infections in solid-organ transplant recipients that pose risk to the graft and to the patient. This study was undertaken to examine the clinical and microbiological spectrum of pneumonia in renal transplant recipients.
    Materials and methods: Of 400 consecutive renal transplant recipients, 87 recipients (21.8%) were hospitalized between November 2014 and October 2016 with pneumonia. We examined demographic profiles and clinical investigations.
    Results: The median age of patients was 38 years (range, 19-72 y). The mean time of presentation after renal transplant was 18 months (range, 1-174 mo). Most patients (80.5%) were on maintenance immunosuppression with tacrolimus, mycophenolate mofetil, and steroids; 34% of patients had an induction agent. Chronic hepatitis C and hepatitis B infections were found in 12.6% and 2.2% of patients, respectively, and new-onset diabetes in 19.5% of patients. Fever (88%), cough (87%), shortness of breath (68%), and hypotension (33%) were common presenting symptoms. Diarrhea was the most frequent accompanying symptom, found in 9.2% of patients. Cytopenia and graft dysfunction were present in 38.7% and 80.4% of patients. Among infections, fungal infections were the most frequent (30%) followed by mixed infections (20.7%), tuberculosis (12.6%), bacterial (12.6%), and viral (3.5%) infections. Etiology could not be found in 27.6% patients. Mortality rate was 24.1%, with the highest rates for fungal infections (44%), followed by bacterial (25%) and mixed infections (18%). Presence of hypoxia and hypotension at presentation was associated with increased risk of death, whereas use of induction agents, new-onset diabetes posttransplant, diabetes mellitus, and acute kidney injury were not correlated with death or increased duration of hospital stay.
    Conclusions: Pneumonia carries high risk of mortality in renal transplant recipients. Fungal and bacterial infections carry high risk of mortality. Despite invasive investigations, a substantial number of patients had unidentified etiology.
    MeSH term(s) Humans ; Young Adult ; Adult ; Middle Aged ; Aged ; Immunosuppressive Agents/adverse effects ; Kidney Transplantation/adverse effects ; Coinfection/chemically induced ; Coinfection/complications ; Mycophenolic Acid/adverse effects ; Diabetes Mellitus/etiology ; Pneumonia/chemically induced ; Mycoses ; Hypotension/etiology ; Transplant Recipients ; Graft Rejection
    Chemical Substances Immunosuppressive Agents ; Mycophenolic Acid (HU9DX48N0T)
    Language English
    Publishing date 2024-02-21
    Publishing country Turkey
    Document type Journal Article
    ZDB-ID 2396778-X
    ISSN 2146-8427 ; 1304-0855
    ISSN (online) 2146-8427
    ISSN 1304-0855
    DOI 10.6002/ect.MESOT2023.P49
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Cost-Effectiveness Analysis of Six Immunotherapy-Based Regimens and Sunitinib in Metastatic Renal Cell Carcinoma: A Public Payer Perspective.

    Yoo, Minkyoung / Nelson, Richard E / Cutshall, Zachary / Dougherty, Maura / Kohli, Manish

    JCO oncology practice

    2023  Volume 19, Issue 3, Page(s) e449–e456

    Abstract: Purpose: Several new treatment combinations have been approved in metastatic renal cell carcinoma (mRCC). To determine the optimal therapy on the basis of cost and health outcomes, we performed a cost-effectiveness analysis of approved immunotherapy- ... ...

    Abstract Purpose: Several new treatment combinations have been approved in metastatic renal cell carcinoma (mRCC). To determine the optimal therapy on the basis of cost and health outcomes, we performed a cost-effectiveness analysis of approved immunotherapy-tyrosine kinase inhibitor/immunotherapy drug combinations and sunitinib using public payer acquisition costs in the United States.
    Methods: We constructed a decision model with a 10-year time horizon. The seven treatment drug strategies included atezolizumab + bevacizumab, avelumab + axitinib, pembrolizumab + axitinib, nivolumab + ipilimumab (NI), nivolumab + cabozantinib, lenvatinib + pembrolizumab, and sunitinib. The effectiveness outcome in our model was quality-adjusted life-years (QALYs) with utility values on the basis of the published literature. Costs included drug acquisition costs and costs for management of grade 3-4 drug-related adverse events. We used a partitioned survival model in which patients with mRCC transitioned between three health states (progression-free, progressive disease, and death) at monthly intervals on the basis of parametric survival function estimated from published survival curves. To determine cost-effectiveness, we constructed incremental cost-effectiveness ratios (ICERs) by dividing the difference in cost by the difference in effectiveness between nondominated treatments.
    Results: The least expensive treatment was sunitinib ($357,948 US dollars [USD]-$656,100 USD), whereas the most expensive was either lenvatinib + pembrolizumab or pembrolizumab + axitinib ($959,302 USD-$1,403,671 USD). NI yielded the most QALYs (3.6), whereas avelumab + axitinib yielded the least (2.5). NI had an incremental ICER of $297,465 USD-$348,516 USD compared with sunitinib. In sensitivity analyses, this ICER fell below $150,000 USD/QALY if the initial 4-month cost of NI decreased by 22%-38%.
    Conclusion: NI was the most effective combination for mRCC, but at a willingness-to-pay threshold of $150,000 USD/QALY, sunitinib was the most cost-effective approach.
    MeSH term(s) Humans ; United States ; Carcinoma, Renal Cell/drug therapy ; Sunitinib/adverse effects ; Nivolumab ; Axitinib/therapeutic use ; Kidney Neoplasms/drug therapy ; Kidney Neoplasms/pathology ; Cost-Effectiveness Analysis ; Immunotherapy
    Chemical Substances Sunitinib (V99T50803M) ; lenvatinib (EE083865G2) ; Nivolumab (31YO63LBSN) ; Axitinib (C9LVQ0YUXG)
    Language English
    Publishing date 2023-01-04
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 3028198-2
    ISSN 2688-1535 ; 2688-1527
    ISSN (online) 2688-1535
    ISSN 2688-1527
    DOI 10.1200/OP.22.00447
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top